Released Aug 12, 2021, after the close
10-Q filed Aug 12, 2021, 43 days after period end · 0001390478-21-000030
Q2 2021 · 10-Q
Revenue$1.90M$1.90M — vs Q2 2020−66.7% vs Q1 2021
Net Income-$4.61M-$4.61M N/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.30-$0.30 N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$4,453,000N/M
Operating Cash Flowderived-$4,898,000N/M
Margins · derived
Operating margin-234.4%
Net margin-242.8%
What the release said
The release
Same quarter
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $1.90M | $0.00 | — | — |
| Net Income | -$4.61M | -$4.43M | -$3.13M | -$6.06M |
| EPS Diluted | -$0.30 | -$0.66 | -$6.33 | -$1.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR